GUARD THERAPEUTICS INTERNATIONAL AB Business Segments Guard Therapeutics International AB
Equities
GUARD
SE0021181559
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.00 SEK | +2.11% |
|
+0.69% | -18.99% |
| 08-29 | First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER | CI |
| 08-27 | Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study | MT |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Biotechnology (Startups) | - | - | - | - | - | |||||
Total Assets | 63.71M | 91.22M | 190M | 203M | 85.23M | |||||
Interest Expense | -872K | -7K | -1K | -1K | -5K | |||||
Income Tax Expense | - | - | - | - | - | |||||
CAPEX | -73K | - | - | - | - | |||||
EBT | -45.16M | -40.28M | -82.03M | -113M | -113M | |||||
D&A | 1.28M | 161K | 15K | 15K | 15K | |||||
Operating Income | -44.28M | -40.28M | -81.9M | -115M | -115M | |||||
Net Income | -45.16M | -40.28M | -82.03M | -113M | -113M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Sweden | - | - | - | - | - | |||||
Total Assets | 63.71M | 91.22M | 190M | 203M | 85.23M | |||||
Interest Expense | -872K | -7K | -1K | -1K | -5K | |||||
Income Tax Expense | - | - | - | - | - | |||||
D&A | 1.28M | 161K | 15K | 15K | 15K | |||||
CAPEX | -73K | - | - | - | - | |||||
Net Income | -45.16M | -40.28M | -82.03M | -113M | -113M | |||||
EBT | -45.16M | -40.28M | -82.03M | -113M | -113M | |||||
Operating Income | -44.28M | -40.28M | -81.9M | -115M | -115M |
MarketScreener is also available in this country: United States.
Switch edition